- Published at
- by investing.com
mixed
mixed
QTTB Stock Touches 52-Week Low at $3.34 Amid Market Challenges By Investing.com
QTTB Stock Touches 52-Week Low at $3.34 Amid Market Challenges
News for Homology Medicines, Inc. (0T6G.L)
- Published at
- by investing.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedInterim Results for the Six Months Ended 30 June 2024
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of...- Published at
- by investing.com
positivepositiveHomology Medicines approves 1-for-18 reverse stock split By Investing.com
Homology Medicines approves 1-for-18 reverse stock split- Published at
- by globenewswire.com
mixedmixedHomology Medicines Declares Distribution to Common Stockholders
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common...- Published at
- by globenewswire.com
mixedmixedSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, SCTL, FIXX, GRPH
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...- Published at
- by globenewswire.com
positivepositiveKuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
Kuehn Law urges FIXX, SCTL, EVRI, and GRPH investors to engage regarding potential mergers, investigating for shareholder value, disclosure, and fairness....- Published at
- by marketscreener.com
mixedmixedSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX -February 27, 2024 at 08:53 pm EST
NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...- Published at
- by globenewswire.com
mixedmixedSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX
NEW YORK, Jan. 27, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...- Published at
- by marketscreener.com
positivepositiveCaribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer
Caribou Biosciences, Inc. announced the appointment of Tim Kelly to the newly created position of chief technology officer. Mr. Kelly brings over 25 years of experience in global clinical and...- Published at
- by globenewswire.com
mixedmixed- Published at
- by globenewswire.com
positivepositiveSHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of PFIN, SRT, FIXX, SMMF to Take Action
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the...- Published at
- by globenewswire.com
mixedmixed- Published at
- by globenewswire.com
positivepositiveSHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of NGAB, FIXX, CNSL, SRT to Take Action
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the...- Published at
- by prnewswire.com
mixedmixedMucopolysaccharidosis Market to Accelerate Substantially, Predicts DelveInsight | Key Companies Working in the Market - Ultragenyx, Abeona, Homology, Denali, LYSOGENE, Allievex, Bellicum, Shire, Taked
/PRNewswire/ -- DelveInsight's Mucopolysaccharidosis Market Insights report includes a comprehensive understanding of current treatment practices,...- Published at
- by globenewswire.com
mixedmixedPhenylketonuria Therapeutics Market is expected to reach US$ 2.28 Billion by 2033, at a growth rate of 8.6% CAGR from 2023 to 2033 | Future Market Insights, Inc
Rising Developments in Newborn Metabolic Screening will propel the Global Market for Phenylketonuria Treatment Market. Increasing Focus on Technological...- Published at
- by globenewswire.com
positivepositive- Published at
- by benzinga.com
mixedmixed69 Biggest Movers From Yesterday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.ZSANYMTXWVEVRCATPTXSTNESRLPRUBYRCMTPOAIPBYIOLMANRIXNINELOVJWELIOVAIMTEHARPGRMMDGRMMGRBXGLTOGBOXFORAFIXXEVFMESGCEFOIDTILCVGWCURIWCURICRTXCOBQBLCMAXDX.MXAXDXAVTXATTOAEYEADAP0T6G.L0JDK.L0H8E.L0A4H.LZUMZW.MXWTALKNXNVTA.MXNVTANVAX.MXNVAXNRXPNMTCDNMTCMRTXMFHKBNTWKBNTIMPHPIMPHOIMHHUSAACOR0JDB.L0A7K.L0A4A.L0A3S.LOKTA.MXOKTAO1KT34.SAJOAN0KB7.L- Published at
- by gurufocus.com
mixedmixedFranklin U.S. Small Capitalization Equity Fund Buys Ovintiv Inc, ShockWave Medical Inc, SM Energy Co, Sells CAI International Inc, Domtar Corp, HubSpot Inc
GuruFocus Article or News written by insider and the topic is about:- Published at
- by gurufocus.com
mixedmixed